Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

NCT03785210 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

22

Enrollment

NIH

Sponsor class

Stopped Study was terminated due to poor accrual.

Conditions

Hepatocellular Carcinoma
Hepatocellular Cancer
Metastatic Pancreatic Cancer
Metastatic Colorectal Cancer
Liver Metastasis

Interventions

DRUG: nivolumab
DRUG: tadalafil
DRUG: oral vancomycin

Sponsor

National Cancer Institute (NCI)